Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Intravitreal conbercept safe, effective against macular oedema secondary to CRVO

07 Aug 2020

Intravitreal conbercept in three monthly loading doses, followed by a pro re nata (PRN) regimen, is safe and effective for patients with macular oedema secondary to central retinal vein occlusion (CRVO), a recent China study has shown.

Researchers enrolled 27 patients (mean age, 52.1±16.1 years; 48 percent male) with macular oedema secondary to CRVO, who contributed 27 eyes for retrospective analysis. Participants were given monthly intravitreal conbercept injections for 3 months, then PRN injections monthly for the next 12 months. The primary outcomes were the change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT).

At baseline, participants had a mean BCVA of 45.1±11.0 letters, which jumped to 57.8±14.7 letters after 3 months of treatment. The mean gain of 12.7±7.6 letters was statistically significant (p<0.001). By month 12, BCVA further improved to 59.9±12.6 letters (mean age, 14.8±9.5 letters; p<0.001).

On the other hand, CRT dropped significantly with treatment, from 707.0±252.3 µm at baseline to 312.5±t80.3 µm at month 3 and to 278.8±68.8 µm at month 12 (p<0.001 for both). Half of the patients saw a reduction in CRT to normal levels after three injections.

Intravitreal conbercept was also safe overall. There were no reports of severe drug-related ocular or systemic adverse events, though mild side effects were recorded. These included conjunctival haemorrhage, vitreous opacity, and temporary elevations in intraocular pressure.

“Larger case numbers, control groups with blank, or other popular anti-[vascular endothelial growth factor] agents may be used to further confirm the conclusion or indicate the difference between conbercept and other type of anti-VEGFs in the management of CRVO,” the researchers said.

Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.